International Society on Thrombosis and Haemostasis/LinkedIn
Aug 29, 2026, 17:05
What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
”Could Factor XI inhibition reshape the future of anticoagulation?
Explore the science behind FXI and FXIa inhibitors, an emerging generation of anticoagulant therapies with the potential to influence future clinical practice.
In this recorded session, Jeff Weitz breaks down:
- The major classes of FXI/FXIa inhibitors
- Where they act within the coagulation cascade
- Leading investigational compounds in clinical trials
- Recent clinical data and key study findings
Animated charts and concise summaries make it easy to follow the evolving evidence and understand where the field may be headed next.
Watch the session on demand.”
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community
-
Aug 29, 2026, 15:49Ujjawal Agarwal: Alkem’s Fight Against Anemia in Rural Bihar